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Abstract
Background: Decision aids are often advocated as a means to assist patient and health care
provider decision making when faced with complicated treatment or screening decisions. Despite
an exponential growth in the availability of decision aids in recent years, their impact on long-term
treatment decisions and patient adherence is uncertain due to a paucity of rigorous studies. The
choice of antithrombotic therapy for nonvalvular atrial fibrillation (NVAF) is one condition for
which a trade-off exists between the potential risks and benefits of competing therapies, and the
need to involve patients in decision making has been clearly identified. This study will evaluate
whether an evidence-based patient decision aid for patients with NVAF can improve the
appropriateness of antithrombotic therapy use by patients and their family physicians.
Design: A multi-center, two-armed cluster randomized trial based in community family practices
in which patients with NVAF will be randomized to decision aid or usual care. Patients will receive
one of four decision aids depending on their baseline stroke risk. The primary outcome is the
provision of "appropriate antithrombotic therapy" at 3 months to study participants
(appropriateness defined as per the 2001 American College of Chest Physicians recommendations
for NVAF). In addition, the impact of this decision aid on patient knowledge, decisional conflict,
well-being, and adherence will be assessed after 3 months, 6 months, and 12 months.
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Background
Atrial fibrillation and anti-thrombotic therapy – the 
evidence
Atrial fibrillation (AF) is a common cardiac arrhythmia,
with a prevalence approaching 2% in the general adult
population [1]. The incidence of atrial fibrillation
increases sharply with age: three-quarters of all patients
with atrial fibrillation are over the age of 65 [1-3]. Patients
with atrial fibrillation have a mortality rate nearly double
that of age and sex matched controls without atrial fibril-
lation, largely due to an increased risk of stroke and sys-
temic emboli [1]. In fact, the risk of stroke in the average
patient with nonvalvular atrial fibrillation (NVAF) is
approximately 5% per year (a five-fold increase in risk
compared to age and sex-matched controls with sinus
rhythm) [4], and 43% to 73% of cardioembolic strokes
result in death or severe neurologic deficit [5].
In the past decade a number of randomized trials have
clearly established that warfarin (relative risk reduction
[RRR] 62%, 95% confidence intervals 48% to 72%), and
to a lesser extent acetylsalicylic acid (ASA) (RRR 22%,
95% confidence intervals 2% to 38%), are highly effica-
cious in the prevention of cardioembolic events in
patients with NVAF [6]. An individual patient meta-anal-
ysis incorporating six of the NVAF trials highlighted the
importance of determining baseline stroke risk in patients
with NVAF given the trade-off between the greater efficacy
of warfarin (hazard ratio for stroke versus ASA of 0.55,
95% CI 0.43–0.71) and the increased bleeding risk
(nearly two fold greater than with ASA) [7]. Thus, in
patients at high risk for stroke, warfarin was clearly more
beneficial than ASA, while in patients at low risk for
stroke, the bleeding risk of warfarin outweighed the
potential benefits. This trial evidence is supported by
health outcomes studies which confirmed the RRR for
warfarin and ASA when used in real world settings is sim-
ilar to that observed in trials [8-13], and a cost-effective-
ness analysis showing that the provision of warfarin
therapy to NVAF patients with additional stroke risk fac-
tors is highly cost-effective [14].
However, antithrombotic therapy is not without risks or
inconveniences. For example, antithrombotic therapy
may impose a number of lifestyle constraints upon
patients (such as the need for regular International Nor-
malized Ratio [INR] monitoring and the avoidance of
potentially hazardous recreational activities when taking
warfarin). Perhaps more importantly, antithrombotic
therapy carries a risk of bleeding (particularly with warfa-
rin). While the risk of major hemorrhage was only mini-
mally increased in warfarin-treated patients in the NVAF
trials (1.3% per year versus 1% per year in placebo-treated
patients), 53–93% of screened patients were excluded
from these trials because of perceived increased bleeding
risk [6].
Risk stratification in the patient with NVAF
As patients differ in their stroke risks at baseline (and thus
differ in their potential to benefit from antithrombotic
therapy), it would be inappropriate to make a blanket rec-
ommendation that all NVAF patients take one therapy or
the other. However, analyses of the pooled data from the
NVAF trials identified a risk stratification scheme which
allows antithrombotic recommendations to be tailored to
the specifics of each case [15,16]. Table 1 outlines a mod-
ification of this risk stratification scheme and the 2001
American College of Chest Physicians (ACCP) antithrom-
botic recommendations for NVAF patients [5]. For the
purposes of this study, treatment will be defined as
"appropriate" if it conforms to the 2001 ACCP recom-
mendations for a patient in that risk strata (for patients on
warfarin, the INR must be in the therapeutic range of 2–
3).
Evidence of a care gap
Practice audits and physician surveys in various settings
have consistently shown that less than half of eligible
patients with NVAF receive antithrombotic therapy. More-
over, even in those who are prescribed warfarin, INRs are
only therapeutic approximately half of the time [10-
13,17].
While the decision to initiate lifelong anticoagulant ther-
apy does (and should) depend on individual patient pref-
erences and some patients may decline proven efficacious
therapies, the weight of evidence in NVAF suggests that
most patients with this condition express clear desires to
avoid stroke and are more willing to take warfarin therapy
than their physicians are to prescribe it [18-23]. While
96% of Canadian physicians agreed that patients should
receive information on the benefits and risks of warfarin
and 86% felt that patients should have a say in whether
warfarin is prescribed, the most frequently cited barriers
to the prescription of warfarin in patients with NVAF were
"patient related barriers" [24]. In particular, the most fre-
quently cited barrier was that "patients would prefer not
to take warfarin due to interference with lifestyle" (72% of
physician respondents) [24]. Other surveys have demon-
strated that clinicians tend to underestimate the benefits
and overestimate the risks of anticoagulation therapy in
atrial fibrillation [25-27].
The potential role of patient-mediated interventions in 
closing care gaps
Numerous studies have suggested that improving patient
knowledge and encouraging their active participation in
treatment decisions may improve their quality of life,
their satisfaction with care, and their compliance withBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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prescribed therapy [18]. It has also been suggested that
patient level interventions (such as decision aids) may be
a means by which to influence clinical practice – in
essence, patients would become the vectors through
which evidence could be transmitted to their clinicians
[18].
Decision support technology is distinct from general
patient education in its focus on the benefits and risks of
alternatives (with explicit discussion of the probability
and consequences of clinically important outcomes), the
tailoring of the information to the particular patient's
clinical risk profile, an emphasis on choice, shared deci-
sion making, consideration of each patient's values
(implicitly or explicitly) during their deliberations, and
the expectation that patients will make a choice after com-
pletion of the exercise [28]. Decision support technolo-
gies vary widely, but audiobooklet decision aids
(consisting of an audiotape, a booklet, a personal work-
sheet, and a physicians' manual summarizing the evi-
dence discussed in the patient booklet) have become a
popular mode. Decision aids serve as adjuncts to physi-
cian counseling, not a replacement. Despite the growing
popularity of decision aids, however, there have been few
studies evaluating their impact and most of these had
methodologic limitations. Indeed, only 30 of the 221
decision aids identified by the Cochrane Consumers and
Communication Group have been tested in randomized
studies (only 5 had usual care control arms), all but 2 of
these trials had potential unit of analysis errors as they
randomized at the level of the patient rather than the
health care provider, and all of these studies were of ques-
tionable generalizability due to their size (median n = 73)
and non-random sampling frames [29]. The impact of
decision aids is thus uncertain and is an area clearly in
need of more investigation. As pointed out by O'Connor:
"optimal study designs should have baseline predisposi-
tions, be randomized, have a control group, clearly define
the decision, and...determine the impact on long-term
decision persistence, health outcomes, health-care utiliza-
tion, and costs" [29].
Work preceding this trial
In an earlier paper [28], Man-Son-Hing et al. described the
development of an antithrombotic decision aid for
patients with NVAF in 1996 (we updated their decision
aid to incorporate new studies published from 1996 to
2001 by systematic reviews of the literature). In a rand-
omized trial enrolling 287 participants from the SPAF III
Trial, this decision aid was shown to improve patient (1)
understanding of the benefits and risks of warfarin and
ASA, (2) their estimates of their individual stroke risk, and
(3) their comfort with their knowledge levels [30]. How-
ever, as the subjects were all being treated within the SPAF
III Trial, the investigators were unable to test whether the
decision aid could influence physician prescribing.
Further, the investigators raised concerns about the gener-
alizability of their results to non-trial participants with
NVAF, who tend to be older and have a higher burden of
comorbidities, and emphasized the need to evaluate this
decision aid in other clinical settings.
Methods
This study is a prospective, multi-center, two-arm cluster
randomized controlled trial being conducted in Edmon-
ton, Ottawa, Toronto, Halifax, and Calgary (all sites in
Canada).
Aim of the study
This study is being done to evaluate whether an evidence-
based patient decision aid for patients with NVAF can
improve the appropriate use of antithrombotic therapy
Table 1: Baseline stroke risk stratification and recommended antithrombotic therapy for patients with nonvalvular atrial fibrillation
Strata Clinical factors Estimated bi-annual stroke 
risk (%)
2001 ACCP recommended 
therapy [5]
Low Age < 65 years, no history of hypertension, heart 
failure or reduced LVEF, or prior systemic emboli
2A S A
Moderate-low Age 65–75 years, no history of hypertension, heart 
failure or reduced LVEF, or prior systemic emboli
4A S A  o r  w a r f a r i n
Moderate-high Age 65–75 years, no history of hypertension, heart 
failure or reduced LVEF, or prior systemic emboli 
but have diabetes mellitus or coronary artery disease
6 Warfarin (target INR 2–3)
High Age ≤ 75 years with history of hypertension or heart 
failure/reduced LVEF OR age > 75 years with no 
history of hypertension, heart failure or reduced 
LVEF, or prior systemic emboli
12 Warfarin (target INR 2–3)
Very High Age > 75 years with history of hypertension or heart 
failure/reduced LVEF OR any age with prior emboli
20 Warfarin (target INR 2–3)
ACCP = American College of Chest Physician LVEF = left ventricular ejection fraction ASA = acetylsalicylic acidBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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(as defined by the 2001 American College of Chest Physi-
cians (ACCP) Recommendations) by patients and their
family physicians [5].
Study design
Cluster randomization (at the level of the family physi-
cian) is being employed in this study such that all eligible
patients within any one physician's practice will be allo-
cated either to active intervention (general educational
session plus patient decision aid and physicians' manual)
or usual care (general educational session). If simple ran-
domization of patients to intervention or usual care were
used, the results could be confounded by contamination
since physicians receive a physician manual for each
patient allocated to the decision aid arm and this may
subsequently influence their management of any usual
care patients in their practice [31].
Randomization to intervention or usual care is being car-
ried out according to a computer-generated sequence
using block randomization (block size of four) with allo-
cation concealment.
Details of the intervention
The decision aid consists of a 30-page booklet, a personal
worksheet, a 50-minute audiotape to guide participants
through the booklet and worksheet, and a 7-page physi-
cians' manual summarizing the evidence discussed in the
patient booklet with a focus on the 2001 ACCP risk strat-
ification schema and recommendations for antithrom-
botic therapy [5]. The details of the development and
validation of the decision aid employed in the study have
already been published [28]. In order to tailor the deci-
sion aid to the circumstances of each participant as closely
as possible, four versions of the decision aid will be avail-
able and patients will receive the version appropriate to
their estimated baseline stroke risk (bi-annual risks of 2%,
4%, 12%, or 20%). All four versions will present the same
background information about AF; the potential conse-
quences of stroke and a major hemorrhage; relative effi-
cacy/bleeding risks with warfarin or aspirin therapy; and
importance of INR monitoring for warfarin therapy. The
baseline risks of stroke, as outlined above, and the esti-
mates of the potential absolute benefits and risks from
warfarin or ASA differ in each version and are presented
graphically and numerically (see Canadian Stroke Net-
work website http://www.canadianstrokenetwork.ca for
electronic copy of the decision aid). The booklet high-
lights key points that are further elaborated upon in the
audiotape. The 1-page personal worksheet is to be com-
pleted by the patient after reviewing the booklet to clarify
their personal values regarding desired outcomes, the
therapy they are inclined to take, their preferred role in the
decision-making process, and to list any questions for
their physician. The family physician of each participant
in the decision aid arm will be sent a physician manual for
insertion into the patient's medical record to assist with
future patient discussions. This physician manual distills
the information presented in the decision aid into a 7-
page document, with an emphasis on the 2001 ACCP risk
stratification scheme and recommended antithrombotic
therapy (Table 1).
If the decision aid is shown to be beneficial, patients in
the control group will be sent a decision aid appropriate
to their risk stratum at the close of the study.
Study setting and recruitment of physicians
A convenience sample of family physicians will be identi-
fied in five urban centers across Canada and approached
for study participation. Those volunteering to participate
will be asked to identify all NVAF patients within their
practice using their practice records (most often billing
records, but some practices with operational electronic
health records will be able to identify eligible patients
through this mechanism).
Patient eligibility criteria
Community-dwelling patients, over the age of 18, will be
included in this study if they have a diagnosis of NVAF
(intermittent or chronic) confirmed by electrocardio-
gram. In those situations where electrocardiograms are
not available, a prescription for digoxin will be accepted
as confirmation of the clinical diagnosis of AF as digoxin
prescriptions have a specificity of 96% to 99% for AF [32].
Patients will be excluded if they: (1) have valvular AF; (2)
are taking warfarin for another condition; (3) are sched-
uled for cardioversion; (4) have a contraindication to war-
farin (pregnancy, women of child-bearing age, history of
bleeding diathesis, gastrointestinal or genitourinary bleed
in past 6 months, history of intracranial bleed, cirrhosis,
esophageal varices, BP ≥ 180/110 mm Hg in last month in
clinic, excessive alcohol intake, daily use of nonsteroidal
anti-inflammatory drug, past intolerance/hypersensitivity
to warfarin); (5) have a contraindication to aspirin (peptic
ulcer disease in past 6 months, past intolerance/hypersen-
sitivity to aspirin); (6) are cognitively impaired (defined
as a score of ≥5 on the Short Portable Mental Status ques-
tionnaire) [33]; (7) if their medications are administered
by a professional caregiver; (8) if their life expectancy is
expected to be less than 12 months; or (9) if they are una-
ble to understand or converse in English.
Study procedures
Following the identification of potential study patients,
each eligible patient will receive a letter signed by their
family physician outlining the study and inviting the
patient's participation. The study team will subsequently
contact any patients who express interest to furtherBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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explain the study, confirm eligibility, invite them to an
educational session, and, in consultation with their family
physician, ascertain each patient's biannual risk of stroke
as per Table 1.
The educational sessions will be conducted by study team
members and will involve a standardized lecture about
NVAF, the risks and consequences of stroke, an overview
of the randomized clinical trial evidence about the aver-
age risks and benefits of antithrombotic therapy in NVAF,
the importance of compliance with prescribed therapy
and, if taking warfarin, the importance of regular moni-
toring of INR. An open-ended question and answer period
will follow each presentation. At the end of the session,
the study will be explained again and written consent will
be obtained from all patients still willing to participate.
Those patients of family physicians allocated to the inter-
vention arm will be given a decision aid with baseline
stroke risk appropriate for their risk stratum, and a set of
questionnaires assessing their willingness to change, their
decisional conflict, and their knowledge about NVAF,
stroke, and the risks/benefits of warfarin and ASA.
Patients of family physicians allocated to the usual care
arm will receive only the questionnaires.
All patients will be contacted by telephone at 3 months, 6
months, and 12 months to determine if they have seen
their primary care physician, to document any changes in
their therapy, and to explore their satisfaction and compli-
ance with their prescribed antithrombotic therapy. Phar-
macy and laboratory/physician records will also be
audited at each scheduled follow-up to confirm anti-
thrombotic use and INR data if on warfarin.
Physicians will receive feedback on their participating
patients' estimated stroke risk (as per Table 1), current
antithrombotic therapy, and, for those patients on warfa-
rin, adequacy of control at 6 months and 12 months. Fig-
ure 1 summarizes the study procedures.
Outcome measures
The primary endpoint will be the use of "appropriate anti-
thrombotic therapy" at 3 months, defined on the basis of
the 2001 ACCP recommendations (see Table 1) [5]. Thus,
patients in the low risk or moderate-low risk strata who
are treated with ASA will be classified as "appropriately
treated". Further, patients who are in any category other
than low risk (including the moderate-low risk strata) and
receive warfarin will be classified as appropriately treated
if their INR is within the therapeutic range (2 to 3) at least
67% of the time (using interpolation methods similar to
those of Rosendaal, incorporating both the frequency of
INR measurement and the actual values) [34,35].
Warfarin-treated patients with INRs which are outside the
therapeutic range more than 1/3 of the time will not be
classified as receiving "appropriate treatment". We chose
two thirds as the cutpoint since patients randomized to
warfarin in the clinical trials had their INRs within target
range on 68% of days [12].
Since there is no widely accepted criterion for how much
time a warfarin-treated patient should be within therapeu-
tic range to be deemed appropriate, we will conduct 2 sen-
sitivity analyses for the primary outcome. First, we will
define "appropriate therapy" for warfarin-treated patients
as having at least one INR measured per month and an
average INR between 2 and 3. Secondly, for warfarin-
treated patients, we will calculate the proportion of time
each patient spends with their INR between 2 and 3 using
the Rosendaal method and will compare the means in
both arms of the trial [34].
Although patients, their family physicians, and the study
investigators will not be blinded to group allocation, out-
comes will be ascertained by a study team member who is
blinded to group assignment.
Secondary endpoints include the following:
• "Appropriate antithrombotic therapy" at 6 months and
12 months
• Patient's readiness to make a choice at baseline – a pre-
viously validated questionnaire [30] will be completed at
baseline to determine the patient's willingness to change
and to assess their beliefs about who should make treat-
ment decisions [see Additional file 1].
• Patient knowledge after intervention – knowledge about
risk of stroke and major bleeding with and without anti-
thrombotic therapy will be tested two weeks after delivery
of the intervention using 8 questions with quantitative
and multiple choice responses which was used in the ear-
lier randomized trial of the NVAF decision aid [see Addi-
tional file 2] [30].
• Decisional conflict – the previously validated O'Connor
Decisional Conflict Scale [36] will be utilized two weeks
after delivery of the intervention to measure the patient's
uncertainty about which therapy to choose, modifiable
factors contributing to uncertainty (believing themselves
to be uninformed, unclear about values, and unsupported
in decision making), and perceived effective decision
making [see Additional file 3].
• Acceptability of decision aid – using 9 questions with
variable responses (ie. short answer, 5-point Likert scale,
yes/no) we will assess patients' views about the acceptabil-
ity of the decision aid with respect to depth, amount, andBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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format, as well as the usefulness of such a tool in making
a decision about therapy [see Additional file 4].
• Satisfaction – patient's satisfaction with current stroke
prevention therapy will be assessed at baseline and at 3, 6,
and 12-months using a 5-point Likert scale.
• Adherence with therapy – the validated Morisky Scale
with a modified 5-point Likert scale response [37] will be
utilized to determine patient adherence with prescribed
antithrombotic therapy at 3, 6, and 12-months.
Sample size
Previous studies suggest that the rate of antithrombotic
use in eligible patients is approximately 60% [17]. How-
ever, the majority of these patients were treated with aspi-
rin. Although only one study [38] has looked at the
"appropriateness" of antithrombotic use (based on the
ACCP risk stratification scheme in use at that time), its
findings closely mirror subgroup analysis from our own
practice audit [39] in that only 33% of NVAF patients
received "appropriate" antithrombotic therapy (as judged
by a panel of clinicians). Thus, it seems reasonable to
hypothesize that the rate of "appropriate antithrombotic
use" will be in the order of 40% for unselected patients.
Assuming that the rate in the control group remains 40%,
and that a 10% absolute increase in antithrombotic use
(to 50% in the intervention group) is clinically significant,
and setting the α error at 0.05 (two-sided) and the β error
at 0.20, a sample size of 814 will be required.
Overview of study procedures Figure 1
Overview of study procedures
Inegligible or declines participation
Follow-up
2 weeks and
3, 6, 12 months
Audit Reports
To physician
at 6 & 12 months
Control
Questionnaires given to Patient
(complete within 2 weeks)
Follow-up
2 weeks and
3,6,12 months
Audit Reports
To physician
at 6 & 12 months
Intervention
Decision aid & questionnaires
(complete within 2 weeks)
Educational Session
Written Consent
Eligible
Agrees to attend educational session
Telephone Interview
Study coordinator to confirm eligibility with 2 weeks of mail out
Patient Identified by Physican
(using billing records, provincial databases, etc.)
Introductory letter signed by physician sent to patient
Physican RecruitmentBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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As there will be some loss of power due to between-cluster
variability, the sample size has to be adjusted to reflect the
cluster randomization [40]. The design effect is the ratio
of the number of subjects required using cluster randomi-
zation versus the number required with simple randomi-
zation and is given by the formula 1+(n-1)p, where n is
the average number of subjects per cluster and p is the
value of the intra-cluster correlation coefficient. Although
the intra-cluster correlation coefficient for the prescription
of antithrombotic therapy in these physicians is
unknown, we can extrapolate from the North of England
Study of Standards and Performance in General Practice
which revealed that the p for prescribing by practitioners
was often less than 0.01 [31]. As we estimate recruiting 10
subjects from each participating physician, the design
effect will be 1+(10-1)0.01 = 1.09. Thus, the required sam-
ple size must be increased to 887.
Allowing for dropouts and losses to follow-up, the sample
size has been adjusted to 1100 (550 in each arm). Assum-
ing that an average of 11 patients is recruited from each
physician's practice, our target sample size is 50 family
physicians in each arm.
Statistical analyses
Intention-to-treat analysis will be carried out. The primary
analysis will be a comparison of the proportion of
patients receiving "appropriate antithrombotic therapy"
in the intervention and usual care groups at 3 months
after intervention. To take into account the cluster rand-
omization, this will be tested using a weighted two sample
t-test [41]. Secondary analyses, again using the weighted
two sample t-test, will compare long-term compliance in
both groups. In order to account for within cluster corre-
lation, a random effects model will be used to assess the
difference between groups on the O'Connor Decisional
Conflict Scale. Similarly, random effects logistic regres-
sion models will be used to investigate what demographic
and clinical factors are associated with the use of "appro-
priate antithrombotic therapy".
An interim analysis will be performed when 3-month fol-
low-up data is available on 400 patients and an independ-
ent External Data Committee will review the results and
make recommendations about any adjustments to sample
size based on the observed cluster size and intra-class cor-
relation coefficient (the study investigators will remain
blinded to the results until after the External Data Com-
mittee makes recommendations).
Data management
All data will be collected using standardized data sheets
and data collation, entry, and quality assurance will be
carried out at the Epidemiology Coordinating and
Research (EPICORE) Centre, Division of Cardiology, Uni-
versity of Alberta. Data analysis will be done by an inde-
pendent statistician in EPICORE blinded to group
allocation.
Ethical considerations
Each patient will be given written information about the
study and written informed consent will be obtained prior
to study inclusion. The study protocol has been approved
by the local Research Ethics Boards of the participating
centers.
Discussion
We report the protocol of a cluster randomized trial that
aims to determine the effect of an antithrombotic decision
aid for patients with NVAF on subsequent use of anti-
thrombotic therapy, patient knowledge, patient deci-
sional conflict and comfort with prescribed treatment,
and medication adherence. This will be the largest rand-
omized trial of a patient decision aid for chronic anti-
thrombotic therapy and only the third trial to evaluate
decision aids via cluster randomization of health care pro-
viders rather than simple randomization of patients. This
trial will provide unique information on the effects of
patient decision aids on long-term adherence with pre-
scribed therapies (the only other two trials to examine the
impact of decision aids on patient adherence with therapy
were small (less than 300 patients) and of short duration
(6 months) [29].
Although it would be preferable to test the decision aid
only in those individuals who are at the point of decision
making (and who are not taking aspirin or warfarin at
baseline), this population would be logistically difficult to
identify and recruitment of sufficient numbers would be
unlikely. Information will be collected about whether
cases are incident or prevalent, and subgroup analysis to
determine whether the decision aid is more effective in
recently diagnosed NVAF patients versus prevalent cases
will be done.
If this decision aid is found to influence provider or
patient behavior, further studies to test the effects of deci-
sion aids in other common conditions (for example,
inhaled steroids in asthma, ACE inhibitors in heart fail-
ure, and statins in hyperlipidemia) will be planned.
The DAAFI investigators are
Steering Committee: F. McAlister, M. Man-Son-Hing
External Data Committee: D. Sackett, K. Teo, A. Laupacis
Central Coordinating Office: M. Fradette, P. Priest, R.
Dupuit, M. Hervas-Malou, S. Blitz, B. LarsonBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/5
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Participating Sites: M. Man-Son-Hing, A. Jessup-Yabsley, J.
Biggs (Ottawa, Canada); F. McAlister, M. Fradette, N. Bell,
T. Bungard (Edmonton, Canada); S. Straus, C. Marquez
(Toronto, Canada); D. Anderson, J. Cox, S. Quinton, A.
McNeil (Halifax, Canada); W. Ghali, P. Gibson, T. Lye
(Calgary, Canada).
Participating Physicians: Ottawa, Canada: J Auer, S Bac-
skai, C Beaulieau, M Berlie, E Biggs, P Boag, D Bowen, E
Brown, J Brisebois, M Buczek, R Bushforth, H Charania, T
Cregan, C D'Amico, C Dechesne, H Dy, M Edirisinghe, E
Elkin, T Faloon, D Finestone, D Guy, D Hans, E Honsl, O
Hughes, S Jaffer, R John, K Jones, D Kahlin, C Khazzam, R
Lacy, B Lemmex, S Litwin, P Lovett, R Maclean, D McDou-
gall, P McGuire, K McIntosh, B Mehta, B Morris, I Oliver,
C O'Neil, I Richardson, A Rosenbloom, M Roy, J Saar, C
Sanderson-Guy, J Schatz, G Schneider, T Shapiro, J Shier,
R Smolkin, N Spencer, B Syposz, R Tee, S Wager, W West-
wick, R Yelle, S Zareef.
Edmonton, Canada: J Bell, N Bell, R Brownoff, G Campbell,
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